Aclarion Technology Advances Global Validation with First Nociscan Exams in LIFEHAB Trial on Low Back Pain
The first six patients in randomized controlled trial completed Nociscan exams
Nociscan on track to be the gold standard for determining which discs to treat in research protocols on low back pain
Aclarion, Inc. (Nasdaq: ACON), a healthcare technology company focused on leveraging biomarkers and augmented intelligence to identify chronic low back pain, announced the completion of the first exams in its ongoing LIFEHAB trial designed to address chronic low back pain. Engaging Aclarion’s gold-standard Nociscan technology, the study is a randomized controlled trial comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation for patients with long-term low back pain.
“We are excited to see the LIFEHAB trial progressing on schedule and look forward to the results of the study and to the role we expect Nociscan data to play in not only helping physicians determine which discs to treat but in potentially helping to predict which treatment option is optimal for a particular patient,” said Aclarion CEO Brent Ness. “Although we talk frequently about driving Nociscan to standard of care for clinical use, the research market is proving to be an early adopter of our technology.”
Key Highlights:
- LIFEHAB Trial: This randomized controlled trial in Norway compares lumbar interbody fusion surgery with multidisciplinary rehabilitation in patients with low back pain that has lasted one year or longer.
- Nociscan’s Role: The technology is being used to assess how magnetic resonance spectroscopy (MRS) biomarkers correspond with treatment response, helping physicians determine the most effective treatment options for each patient.
- Progress: The first six patients have completed their Nociscan exams, and the trial remains on track for further results.
- Growing Research Adoption: Nociscan has also been selected for studies in Rome and by the National Institutes of Health (NIH), further demonstrating its potential to become the gold standard in determining which discs to treat and to continue to transform global treatment strategies.
In addition to the LIFEHAB trial, Aclarion is magnifying its market reach, recently securing its first commercial agreement in Michigan with Sheridan Community Hospital. Aclarion also expanded its partnership with The London Clinic, increasing access throughout the London market. With private payer coverage from major UK insurers, including AXA, Aviva and Vitality, Aclarion now reaches 60% of private health insurance patients in Greater London.
At the same time, Aclarion is advancing its CLARITY trial, set to enroll up to 300 patients with early data expected in H1 2026. This will further validate Nociscan’s effectiveness in helping surgeons decide on the optimal surgical treatment to improve patient outcomes and its global adoption.
Disclaimer
This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
